- Home
- FMNB vs ZNTL Comparison
FMNB vs ZNTL Comparison
Compare FMNB & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FMNB | ZNTL |
|---|---|---|
| Founded | 1887 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 555.3M | 468.9M |
| IPO Year | 2010 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FMNB | ZNTL |
|---|---|---|
| Price | $13.96 | $5.20 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $14.33 | $6.60 |
| AVG Volume (30 Days) | 357.2K | ★ 3.6M |
| Earning Date | 04-24-2026 | 05-13-2026 |
| Dividend Yield | ★ 4.90% | N/A |
| EPS Growth | ★ 18.85 | 18.03 |
| EPS | ★ 1.45 | N/A |
| Revenue | ★ $279,922,000.00 | N/A |
| Revenue This Year | $52.63 | N/A |
| Revenue Next Year | $8.28 | N/A |
| P/E Ratio | $9.58 | ★ N/A |
| Revenue Growth | ★ 3.89 | N/A |
| 52 Week Low | $12.19 | $1.13 |
| 52 Week High | $15.50 | $6.95 |
Technical Indicators
Market Signals| Indicator | FMNB | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 69.34 | 67.76 |
| Support Level | $12.99 | $1.31 |
| Resistance Level | $14.36 | N/A |
| Average True Range (ATR) | 0.25 | 0.63 |
| MACD | 0.11 | 0.36 |
| Stochastic Oscillator | 97.92 | 64.04 |
Price Performance
Historical ComparisonAbout FMNB Farmers National Banc Corp.
Farmers National Banc Corp is a one-bank holding company engaged in financial activities, including securities underwriting and dealing, insurance agency and underwriting activities, and merchant banking activities. It operates in the domestic banking, trust, retirement consulting, insurance, and financial management industries. The company has two operating segments of business; the Bank segment, and the Trust segment, out of which the majority of the company's revenue is derived from the bank segment.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.